Investigational New Drugs

, 27:120

Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer

  • Manon Buijs
  • Josephina A. Vossen
  • Jean-Francois H. Geschwind
  • Takayoshi Ishimori
  • James M. Engles
  • Obele Acha-Ngwodo
  • Richard L. Wahl
  • Mustafa Vali
PRECLINICAL STUDIES

DOI: 10.1007/s10637-008-9145-0

Cite this article as:
Buijs, M., Vossen, J.A., Geschwind, JF.H. et al. Invest New Drugs (2009) 27: 120. doi:10.1007/s10637-008-9145-0

Summary

Purpose: To evaluate the anti-glycolytic effects of 3-BrPA on rats bearing RMT mammary tumors, by determining FDG uptake after intravenous administration of the therapeutic dose. Materials and Methods: Sixteen rats bearing RMT tumors were treated either with 15 mM 3-BrPA in 2.5 ml of PBS or with 2.5 ml of PBS. After treatment, all rats received FDG and were sacrificed 1 h later. Results: 3-BrPA treatment significantly decreased FDG uptake in tumors by 77% (p = 0.002). FDG uptake did not significantly decrease in normal tissues after treatment. Conclusion: Our study showed that 3-BrPA exhibits a strong anti-glycolytic effect on RMT cells implanted in rats.

Keywords

Breast cancer3-BromopyruvateFDGRMTAnimal model

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Manon Buijs
    • 1
  • Josephina A. Vossen
    • 1
  • Jean-Francois H. Geschwind
    • 1
  • Takayoshi Ishimori
    • 1
  • James M. Engles
    • 1
  • Obele Acha-Ngwodo
    • 1
  • Richard L. Wahl
    • 1
  • Mustafa Vali
    • 1
  1. 1.Russell H. Morgan Department of Radiology, and Radiological SciencesDivision of Vascular and Interventional RadiologyBaltimoreUSA